论文部分内容阅读
目的观察普萘洛尔对人三阴性乳腺癌细胞MDA-MB-231化疗的增敏作用。方法采用MTT比色法检测紫杉醇或阿霉素单用和与普萘洛尔联用的细胞增殖抑制率,并计算其半数抑制浓度IC50值;采用流式细胞术,通过Annexin V-FITC/PI双染法检测细胞凋亡率。结果不同浓度的紫杉醇或阿霉素联合普萘洛尔后,其细胞增殖抑制率均明显升高,并呈剂量依赖性,其IC50值均下降,差异均有统计学意义(P<0.05);紫杉醇联合普萘洛尔后,其细胞凋亡率由(35.7±2.9)%上升至(53.8±3.9)%,阿霉素联合普萘洛尔后,其细胞凋亡率由(41.6±1.3)%上升至(69.8±4.7)%,差异均有统计学意义(P<0.05)。结论普萘洛尔与阿霉素或紫杉醇联用可协同抑制人三阴性乳腺癌细的增殖,促进其凋亡。
Objective To observe the sensitizing effect of propranolol on human triple negative breast cancer cell line MDA-MB-231. Methods MTT assay was used to detect the inhibition rate of paclitaxel or doxorubicin alone and in combination with propranolol, and the IC50 value of half-inhibitory concentration (IC50) was calculated. Flow cytometry was used to detect the IC50 value of Annexin V-FITC / PI Double staining method was used to detect the apoptosis rate. Results Paclitaxel or doxorubicin combined with propranolol inhibited the cell proliferation significantly and in a dose-dependent manner. The IC50 values of all groups were significantly decreased (P <0.05). Paclitaxel After combined with propranolol, the rate of apoptosis increased from (35.7 ± 2.9)% to (53.8 ± 3.9)%, and the apoptosis rate increased from (41.6 ± 1.3)% to (69.8 ± 4.7)%, the difference was statistically significant (P <0.05). Conclusion Propranolol combined with doxorubicin or paclitaxel can synergistically inhibit the proliferation of human triple negative breast cancer cells and promote their apoptosis.